Orchard Therapeutics PLC
Ben Conti is a finance professional with extensive experience in the biotechnology and healthcare sectors. Currently serving as Director of Finance at Orchard Therapeutics since May 2020, Ben has progressed through various finance roles including Associate Director and Senior Manager of Finance Operations. Prior experience includes leadership positions at Sensyne Health from February 2019 to April 2020, where Ben held the titles of Head of Group Financial Reporting and Group Financial Reporting Manager. Prior to this, Ben worked at PwC from September 2013 to January 2019, advancing from Associate to Manager. Ben holds the ACA qualification from ICAEW (2013-2016) and a Master of Mathematics (MMath) in Mathematics from Durham University (2008-2012).
This person is not in the org chart
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.